MX2022005033A - Terapia combinada antitumoral que comprende un anticuerpo anti grupo de diferenciación 19 (cd19) y linfocitos t gamma delta. - Google Patents
Terapia combinada antitumoral que comprende un anticuerpo anti grupo de diferenciación 19 (cd19) y linfocitos t gamma delta.Info
- Publication number
- MX2022005033A MX2022005033A MX2022005033A MX2022005033A MX2022005033A MX 2022005033 A MX2022005033 A MX 2022005033A MX 2022005033 A MX2022005033 A MX 2022005033A MX 2022005033 A MX2022005033 A MX 2022005033A MX 2022005033 A MX2022005033 A MX 2022005033A
- Authority
- MX
- Mexico
- Prior art keywords
- lymphocytes
- antibody
- differentiation
- combined
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19206479 | 2019-10-31 | ||
| PCT/EP2020/080494 WO2021084063A1 (en) | 2019-10-31 | 2020-10-30 | Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022005033A true MX2022005033A (es) | 2022-09-09 |
Family
ID=68424789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022005033A MX2022005033A (es) | 2019-10-31 | 2020-10-30 | Terapia combinada antitumoral que comprende un anticuerpo anti grupo de diferenciación 19 (cd19) y linfocitos t gamma delta. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20210130461A1 (enExample) |
| EP (2) | EP4706673A3 (enExample) |
| JP (2) | JP7688025B2 (enExample) |
| KR (1) | KR20220116154A (enExample) |
| CN (1) | CN115151565A (enExample) |
| AU (1) | AU2020372646A1 (enExample) |
| DK (1) | DK4051710T3 (enExample) |
| ES (1) | ES3062643T3 (enExample) |
| FI (1) | FI4051710T3 (enExample) |
| HR (1) | HRP20251630T1 (enExample) |
| IL (1) | IL292213A (enExample) |
| LT (1) | LT4051710T (enExample) |
| MA (1) | MA69251B1 (enExample) |
| MD (1) | MD4051710T2 (enExample) |
| MX (1) | MX2022005033A (enExample) |
| PH (1) | PH12022551009A1 (enExample) |
| PL (1) | PL4051710T3 (enExample) |
| PT (1) | PT4051710T (enExample) |
| RS (1) | RS67602B1 (enExample) |
| SI (1) | SI4051710T1 (enExample) |
| SM (1) | SMT202600082T1 (enExample) |
| TW (2) | TWI922280B (enExample) |
| WO (1) | WO2021084063A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016311136B2 (en) | 2015-08-21 | 2022-02-17 | Incyte Corporation | Combinations and uses thereof |
| ES2981046T3 (es) | 2016-05-30 | 2024-10-07 | Incyte Corp | Métodos para predecir el beneficio terapéutico de una terapia anti-CD19 en pacientes |
| SMT202100317T1 (it) | 2016-06-27 | 2021-07-12 | Morphosys Ag | Formulazioni di anticorpi anti-cd19 |
| WO2018078123A1 (en) | 2016-10-28 | 2018-05-03 | Morphosys Ag | Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| KR102617497B1 (ko) | 2022-09-15 | 2023-12-27 | 주식회사 엘지에너지솔루션 | 음극용 자성 정렬 장치 및 이를 이용한 음극의 제조방법 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ，インコーポレイティド | 人工抗体ポリペプチド |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| JP4733635B2 (ja) | 2003-07-31 | 2011-07-27 | イミューノメディクス、インコーポレイテッド | 抗ｃｄ１９抗体 |
| WO2007002223A2 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
| AU2006332155B2 (en) | 2005-12-30 | 2013-01-10 | Cancer Research Technology Limited | Anti-CD19 antibodies with reduced immunogenicity |
| RS53263B (sr) | 2006-08-14 | 2014-08-29 | Xencor Inc. | Optimizovana antitela usmerena na cd19 |
| US8323653B2 (en) | 2006-09-08 | 2012-12-04 | Medimmune, Llc | Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| CA2693053C (en) | 2007-05-30 | 2021-01-05 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| CN101903403B (zh) | 2007-10-19 | 2016-03-16 | 西雅图基因公司 | Cd19结合剂及其应用 |
| CA2753158A1 (en) | 2009-02-23 | 2010-08-26 | Glenmark Pharmaceuticals S.A. | Humanized antibodies that bind to cd19 and their uses |
| WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
| EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
| EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
| US8940707B2 (en) | 2010-10-28 | 2015-01-27 | Viropharma Incorporated | Maribavir isomers, compositions, methods of making and methods of using |
| EP2524929A1 (en) | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| EP2710123B1 (en) | 2011-05-19 | 2017-07-12 | Instituto de Medicina Molecular | Cell line of lymphocytes comprising gamma-delta t cells, composition and production method thereof |
| EP3157553A4 (en) * | 2014-06-16 | 2018-02-28 | Xencor, Inc. | Treatment for chronic lymphocytic leukemia (cll) |
| RU2756247C2 (ru) | 2014-11-17 | 2021-09-28 | Эдисет Био, Инк. | Генетически модифицированные гамма дельта т-клетки |
| JP6916741B2 (ja) * | 2015-05-26 | 2021-08-11 | モルフォシス・アーゲー | 抗ｃｄ１９抗体およびブルトン型チロシンキナーゼ阻害剤の組み合わせ、およびその使用 |
| JP6799895B2 (ja) | 2015-06-09 | 2020-12-16 | リンファクト−リンフォサイト アクティベイション テクノロジーズ エス．エー． | ＴＣＲγδ＋Ｔ細胞の生産方法 |
| CN108473958A (zh) | 2015-10-30 | 2018-08-31 | 癌症研究技术有限公司 | 非造血组织驻留γδT细胞的扩增及这些细胞的用途 |
| CN118421557A (zh) | 2016-05-12 | 2024-08-02 | 阿迪塞特治疗公司 | 选择性扩增γδT细胞群的方法及其组合物 |
| SMT202100317T1 (it) | 2016-06-27 | 2021-07-12 | Morphosys Ag | Formulazioni di anticorpi anti-cd19 |
| WO2018078123A1 (en) * | 2016-10-28 | 2018-05-03 | Morphosys Ag | Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof |
| EP3532091A2 (en) * | 2016-10-29 | 2019-09-04 | H. Hoffnabb-La Roche Ag | Anti-mic antibidies and methods of use |
| GB201707048D0 (en) | 2017-05-03 | 2017-06-14 | King S College London | Expansion of gamma delta cells, compositions, and methods of use thereof |
| TWI687227B (zh) * | 2017-10-03 | 2020-03-11 | 生倍科技股份有限公司 | 用於t細胞免疫療法之組合及其用途 |
-
2020
- 2020-10-30 LT LTEPPCT/EP2020/080494T patent/LT4051710T/lt unknown
- 2020-10-30 IL IL292213A patent/IL292213A/en unknown
- 2020-10-30 EP EP25217971.8A patent/EP4706673A3/en active Pending
- 2020-10-30 MX MX2022005033A patent/MX2022005033A/es unknown
- 2020-10-30 TW TW114114410A patent/TWI922280B/zh active
- 2020-10-30 RS RS20251350A patent/RS67602B1/sr unknown
- 2020-10-30 EP EP20800121.4A patent/EP4051710B1/en active Active
- 2020-10-30 MA MA69251A patent/MA69251B1/fr unknown
- 2020-10-30 PL PL20800121.4T patent/PL4051710T3/pl unknown
- 2020-10-30 CN CN202080090109.2A patent/CN115151565A/zh active Pending
- 2020-10-30 PT PT208001214T patent/PT4051710T/pt unknown
- 2020-10-30 WO PCT/EP2020/080494 patent/WO2021084063A1/en not_active Ceased
- 2020-10-30 MD MDE20220968T patent/MD4051710T2/ro unknown
- 2020-10-30 US US17/084,783 patent/US20210130461A1/en active Pending
- 2020-10-30 AU AU2020372646A patent/AU2020372646A1/en active Pending
- 2020-10-30 KR KR1020227018073A patent/KR20220116154A/ko active Pending
- 2020-10-30 TW TW109137982A patent/TWI883067B/zh active
- 2020-10-30 JP JP2022525535A patent/JP7688025B2/ja active Active
- 2020-10-30 HR HRP20251630TT patent/HRP20251630T1/hr unknown
- 2020-10-30 FI FIEP20800121.4T patent/FI4051710T3/fi active
- 2020-10-30 PH PH1/2022/551009A patent/PH12022551009A1/en unknown
- 2020-10-30 SI SI202030692T patent/SI4051710T1/sl unknown
- 2020-10-30 SM SM20260082T patent/SMT202600082T1/it unknown
- 2020-10-30 DK DK20800121.4T patent/DK4051710T3/da active
- 2020-10-30 ES ES20800121T patent/ES3062643T3/es active Active
-
2025
- 2025-05-22 JP JP2025085318A patent/JP2025134705A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MA69251B1 (fr) | 2025-12-31 |
| TW202547555A (zh) | 2025-12-16 |
| WO2021084063A1 (en) | 2021-05-06 |
| DK4051710T3 (da) | 2025-12-15 |
| AU2020372646A1 (en) | 2022-05-12 |
| PH12022551009A1 (en) | 2023-03-20 |
| SI4051710T1 (sl) | 2026-01-30 |
| KR20220116154A (ko) | 2022-08-22 |
| ES3062643T3 (en) | 2026-04-13 |
| TWI883067B (zh) | 2025-05-11 |
| IL292213A (en) | 2022-06-01 |
| JP7688025B2 (ja) | 2025-06-03 |
| EP4706673A3 (en) | 2026-05-20 |
| EP4051710B1 (en) | 2025-11-26 |
| LT4051710T (lt) | 2026-03-10 |
| CA3158984A1 (en) | 2021-05-06 |
| TWI922280B (zh) | 2026-04-11 |
| US20210130461A1 (en) | 2021-05-06 |
| RS67602B1 (sr) | 2026-01-30 |
| SMT202600082T1 (it) | 2026-03-09 |
| JP2022554324A (ja) | 2022-12-28 |
| CN115151565A (zh) | 2022-10-04 |
| PL4051710T3 (pl) | 2026-04-20 |
| JP2025134705A (ja) | 2025-09-17 |
| HRP20251630T1 (hr) | 2026-02-13 |
| TW202131949A (zh) | 2021-09-01 |
| PT4051710T (pt) | 2026-02-09 |
| EP4051710A1 (en) | 2022-09-07 |
| EP4706673A2 (en) | 2026-03-11 |
| MD4051710T2 (ro) | 2026-04-30 |
| FI4051710T3 (fi) | 2026-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019012032A (es) | Tratamiento de tumores positivos a gen 3 de activacion de linfocitos (lag-3). | |
| EP4140502A4 (en) | ONCOLYTIC VIRUS IN COMBINATION WITH AN IMMUNE CHECKPOINT INHIBITOR FOR THE TREATMENT OF TUMORS | |
| CL2018000853A1 (es) | Terapia de combinación de inhibidores de bromodominios y bloqueo de puntos de control inmunitarios para tratar el cáncer. | |
| MX2021002888A (es) | Combinaciones farmacéuticas para el tratamiento de tumores que comprenden un anticuerpo anti cúmulo de diferenciación 19 (cd19) y una célula asesina natural. | |
| PH12021551282A1 (en) | Radioimmunoconjugates and checkpoint inhibitor combination therapy | |
| CO2020013600A2 (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak | |
| MX2017000627A (es) | Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe). | |
| EP4286009A3 (en) | Oncolytic vaccinia virus and checkpoint inhibitor combination therapy | |
| AR112556A1 (es) | Concepto para generar una descripción mejorada de campo de sonido o un campo de sonido modificado | |
| ECSP21052194A (es) | Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp | |
| ZA201808537B (en) | Combination therapies | |
| BR112021012056A2 (pt) | Inibidor da expressão gênica do hbv, agente que reduz a carga antigênica de hbv, composições para uso no tratamento de uma infecção crônica por hbv, usos de um inibidor da expressão gênica do hbv e de um agente que reduz a carga antigênica de hbv, métodos de tratamento da infecção crônica por hbv e kit | |
| MX2016011975A (es) | Metodos para reducir el riesgo cardiovascular. | |
| CL2022002479A1 (es) | Una terapia combinada con nirogacestat y una terapia dirigida a bcma y usos de estas | |
| MX390955B (es) | Uso de un anticuerpo anti-pd-1 en combinación con un anticuerpo anti-cd30 para el tratamiento de linfoma. | |
| MX2021008268A (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r. | |
| MX2022005031A (es) | Terapia anti cumulo de diferenciacion 19(cd19) en combinacion con lenalidomida para el tratamiento de leucemias o linfomas. | |
| EP3888648A4 (en) | TREATMENT OF CANCER BY COMBINATION OF IMMUNE CHECKPOINT INHIBITOR AND FOLFIRINOX THERAPY | |
| BR112018013063A2 (pt) | combinação terapêutica inibidora de bromodomínio e proteína extra-terminal | |
| CH458843A (de) | Vorrichtung zur Isolation gegen Stösse und Erschütterungen | |
| CL2021001246A1 (es) | Moduladores de expresión irf5. | |
| MA69251B1 (fr) | Thérapie combinée antitumorale comprenant un anticorps anti-cd19 et des cellules t gamma delta | |
| DOP2021000215A (es) | Tratamiento de la cefalea usando anticuerpo anti-cgrp | |
| ES2055314T3 (es) | Tratamiento de disfuncion leucocitaria con gm-csf. | |
| MX2020008415A (es) | Metodos y composiciones que actuan de forma selectiva sobre linfocitos treg. |